Altace / Ramipril

Modified on 2009/10/14 21:49 by admin
Altace, also known as Ramipril, is marketed by Aventis Pharmaceuticals. The Food & Drug Administration approved Altace for use in hyper-tensive patients in 1991. In 2000, the FDA approved its use to reduce the risk of myocardial infarction, stroke and death from cardiovascular causes.

Altace is classified as an ACE inhibitor. An ACE inhibitor blocks the body's production of angiotensin-converting enzymes (ACE), a chemical needed by the body to make angiotensin II, a chemical that increases blood pressure by narrowing arteries. This process leaves blood vessels more relaxed, which decreases blood pressure and increases the flow of blood and oxygen to the heart. Altace is primarily used for treatment of high blood pressure, although it is sometimes used to slow the weakening of the heart in patients who recently suffered heart attacks.

Studies have associated Altace with fetal and neo-natal injury and death when used by women in their second and third trimester. Also, Altace may have adverse effects on liver and kidney function.

See your doctor if you have experienced serious side effects associated with Altace. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Blood Pressure Drugs: Overview
  2. Children's Health Matters: Overview
  3. Kidney Failure
  4. Liver Problems
  Name Size